ANDA 65348, held by Cephazone Pharma. Cefotaxime Sodium.
As of Nov 21, 2026, ANDA 65348 (Cefotaxime Sodium), held by Cephazone Pharma, was first approved by FDA on Jan 25, 2010, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 25, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cefotaxime SodiumEQ 10GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters